Lux Biosciences
Jersey City, New Jersey, United States
About Lux Biosciences
Lux Biosciences, Inc., a biotechnology company, develops medications to treat ophthalmic diseases. Its products include LX201, a silicone matrix ocular implant that enables the release of cyclosporine A to the eye for one year; Luveniq, an oral form of calcineurin inhibitor voclosporin; LX212, a bioerodible polymer implant that contains voclosporin; and LX214, a topical mixed nanomicellar formulation of voclosporin therapy for dry eyes. The company was founded in 2005 and is based in Jersey City, New Jersey.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $129.2M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Mar 2012)
- Website: luxbio.com
- Phone: 201-946-0551
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/lux-biosciences-2480188 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.